SELLAS Life Sciences Group, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-09-30 was -$8.65M, a 721.70% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-03-31 was $1.63M, a 66.12% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2017-12-31 was -$5.01M, a 133.74% decline year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2017-09-30 was $1.39M.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2017 was $1.29M, a 91.60% decline from fiscal 2016.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2016 was $15.41M.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2014 was $37.74M, a 71.06% increase from fiscal 2013.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2013 was $22.06M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2018-09-30 | -$8.65M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $1.63M 10-Q · filed 2019-05-15 | -$1.89M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $1.29M 10-K · filed 2019-03-22 |
| 2017-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $21.16M derived: sum of 4 quarters · filed 2018-04-13 |
| 2017-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $19.77M derived: sum of 4 quarters · filed 2018-04-13 |
| 2017-03-31 | $4.81M 10-Q · filed 2017-05-10 | $20.18M derived: sum of 4 quarters · filed 2018-04-13 |
| 2016-12-31 | $14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | $15.41M 10-K · filed 2018-04-13 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2016-06-30 | $511.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | |
| 2016-03-31 | $46.00K 10-Q · filed 2016-05-10 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2014-12-31 | $48.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $37.74M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$47.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-07 | $8.88M derived: sum of 4 quarters · filed 2016-04-15 |
| 2014-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | |
| 2014-03-31 | $37.42M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $19.17M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $22.06M 10-K/A · filed 2016-04-15 |
| 2012-12-31 | $16.55M 8-K · filed 2015-12-04 | |
| 2011-12-31 | $3.27M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |